Equity Litigation Group Reveals Settlement in NGM Biopharmaceuticals Stockholder Class Action

Equity Litigation Group LLP Reveals Settlement in NGM Biopharmaceuticals Class Action

Equity Litigation Group LLP has made significant strides in resolving a stockholder class action related to NGM Biopharmaceuticals, Inc. As per the court documents filed in the Delaware Court of Chancery, this action pertains to stockholders who held shares in NGM, particularly around the time of its take-private transaction.

The class action lawsuit, initiated by Charles Bryant against pivotal figures and entities involved, seeks to address grievances from stockholders who either received cash payouts or dissented from the transaction. The proposed settlement offers a sum of $6 million, aimed at alleviating the claims brought forth against the defendants—The Column Group, LP, David V. Goeddel, and David J. Woodhouse.

The timeline is crucial for anyone potentially affected by this settlement. According to the court's schedule, a settlement hearing is set to take place on October 21, 2025. This hearing will not only evaluate the fairness and reasonableness of the proposed settlement but also finalize the appointment of counsel and class representatives. Investors who hold or have held shares of NGM Biopharmaceuticals around the transaction date are advised to stay engaged as updates will be posted at the designated settlement website.

The Stipulation and Agreement of Settlement, which outlines the details of the agreement, is accessible online, allowing stakeholders to familiarize themselves with the terms. Included in this document will be information regarding the distribution of the Net Settlement Fund, calculated on a pro-rata basis according to the number of shares each class member held at the time.

As the October hearing approaches, it is essential for all class members to act accordingly. Responses to the proposed settlement or concerns regarding the allocation plan must be submitted by October 7, 2025. This provides a narrow window for stakeholders to voice any objections or seek clarifications regarding their potential entitlements under the class action settlement.

It is important to note that participants in the stockholder class action do not need to file claims to receive potential settlement payments. Eligible members as defined in the settlement documents will automatically be considered for distribution from the Net Settlement Fund based on the shares they held during the specified timeframe.

In summary, while this settlement marks a critical juncture for stockholders of NGM Biopharmaceuticals, it is a reminder of the complexities surrounding corporate transactions and the responsibilities of entities involved. Stakeholders should remain vigilant and informed as the details unfold leading up to the settlement hearing. Those affected are encouraged to visit the online settlement portal for further information and updates, ensuring they have all the necessary resources to understand their rights and potential payouts from this lawsuit.